Clinical Trial Update: A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating continuous subcutaneous insulin infusion pump function with recombinant human hyaluronidase (rHuPH20) in people with Type 1 Diabetes; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Recombinant human hyaluronidase (rHuPH20) (recombinant human hyaluronidase)

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Type 1 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2019-02-01